YUJIN PARK - Publications

Affiliations: 
 

5 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Ullah S, Park C, Ikram M, Kang D, Lee S, Yang J, Park Y, Yoon S, Chun P, Moon HR. Tyrosinase inhibition and anti-melanin generation effect of cinnamamide analogues. Bioorganic Chemistry. 87: 43-55. PMID 30856375 DOI: 10.1016/j.bioorg.2019.03.001  0.36
2018 Ullah S, Kang D, Lee S, Ikram M, Park C, Park Y, Yoon S, Chun P, Moon HR. Synthesis of cinnamic amide derivatives and their anti-melanogenic effect in α-MSH-stimulated B16F10 melanoma cells. European Journal of Medicinal Chemistry. 161: 78-92. PMID 30347330 DOI: 10.1016/j.ejmech.2018.10.025  0.36
2018 Kim JY, Park Y, Lee BM, Kim HS, Yoon S. P-gp Inhibition by the Anti-psychotic Drug Pimozide Increases Apoptosis, as well as Expression of pRb and pH2AX in Highly Drug-resistant KBV20C Cells. Anticancer Research. 38: 5685-5692. PMID 30275188 DOI: 10.21873/anticanres.12905  0.36
2017 Park Y, Son JY, Lee BM, Kim HS, Yoon S. Highly Eribulin-resistant KBV20C Oral Cancer Cells Can Be Sensitized by Co-treatment with the Third-generation P-Glycoprotein Inhibitor, Elacridar, at a Low Dose. Anticancer Research. 37: 4139-4146. PMID 28739698  0.36
2016 Lim JS, Park Y, Lee BM, Kim HS, Yoon S. Co-treatment with Celecoxib or NS398 Strongly Sensitizes Resistant Cancer Cells to Antimitotic Drugs Independent of P-gp Inhibition. Anticancer Research. 36: 5063-5070. PMID 27798865  0.36
Show low-probability matches.